Ana Ciszek, MD
Internal Medicine · Venice, FLNPI 1083979942
Payments from drug & device makers
Across 217 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$444
- Amgen$421
- Lilly USA, LLC$330
- AbbVie$319
- Exact Sciences$302
- Pfizer$217
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $444 |
| Amgen | 25 | $421 |
| Lilly USA, LLC | 20 | $330 |
| AbbVie(2 entities) | 17 | $319 |
| Exact Sciences | 11 | $302 |
| Pfizer | 15 | $217 |
| Astellas Pharma US Inc | 12 | $168 |
| Boehringer Ingelheim | 12 | $167 |
| Kowa Pharmaceuticals America, Inc. | 9 | $127 |
| GSK | 8 | $119 |
| Bayer | 5 | $114 |
| AstraZeneca | 9 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $111 |
| Amarin Pharma, Inc. | 6 | $103 |
| Boston Scientific | 3 | $98 |
| Radius Health, Inc. | 5 | $72 |
| Merck | 5 | $61 |
| Johnson & Johnson | 3 | $57 |
| GRT US Holding, Inc. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| IBSA Pharma Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$3,699 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $116,578 |
| EliquisApixaban | 97 | $108,459 |
| JardianceEmpagliflozin | 30 | $46,518 |
| XareltoRivaroxaban | 25 | $39,707 |
| MounjaroTirzepatide | 22 | $28,688 |
| FarxigaDapagliflozin Propanediol | 16 | $27,336 |
| ProliaDenosumab | 13 | $22,501 |
| JanuviaSitagliptin Phosphate | 14 | $22,354 |
| MyrbetriqMirabegron | 21 | $21,077 |
| TrulicityDulaglutide | 14 | $16,810 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $15,965 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $13,649 |
| Repatha SureclickEvolocumab | 16 | $13,012 |
| SynthroidLevothyroxine Sodium | 125 | $8,126 |
| Rosuvastatin Calcium | 457 | $5,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $444 | $116,57858 claims |
| PfizerEliquis, Premarin, Paxlovid | $217 | $116,043133 claims |
| Boehringer IngelheimJardiance | $167 | $46,51830 claims |
| Lilly USA, LLCMounjaro, Trulicity | $330 | $45,49736 claims |
| Johnson & JohnsonXarelto | $57 | $39,70725 claims |
| GSKBreo Ellipta, Anoro Ellipta | $119 | $29,61437 claims |
| AstraZenecaFarxiga | $114 | $27,33616 claims |
| AmgenProlia | $421 | $22,50113 claims |
| MerckJanuvia | $61 | $22,35414 claims |
| Astellas Pharma US IncMyrbetriq | $168 | $21,07721 claims |
| AbbVieSynthroid | $319 | $8,126125 claims |
| IBSA Pharma Inc.Tirosint | $46 | $1,50812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Venice
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.